



Patient selection for whole brain radiotherapy (WBRT)
in a large lung cancer cohort: Impact of a new Dutch
guideline on brain metastases
Citation for published version (APA):
Hendriks, L. E. L., Troost, E. G. C., Steward, A., Bootsma, G. P., De Jaeger, K., van den Borne, B. E. E.
M., & Dingemans, A-M. C. (2014). Patient selection for whole brain radiotherapy (WBRT) in a large lung
cancer cohort: Impact of a new Dutch guideline on brain metastases. Acta Oncologica, 53(7), 945-951.
https://doi.org/10.3109/0284186X.2014.906746





Publisher's PDF, also known as Version of record
Document license:
Taverne
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.




Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 03 Nov. 2021
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=ionc20
Acta Oncologica
ISSN: 0284-186X (Print) 1651-226X (Online) Journal homepage: https://www.tandfonline.com/loi/ionc20
Patient selection for whole brain radiotherapy
(WBRT) in a large lung cancer cohort: Impact of a
new Dutch guideline on brain metastases
Lizza E. L. Hendriks, Esther G. C. Troost, Allan Steward, Gerben P. Bootsma,
Katrien De Jaeger, Ben E. E. M. van den Borne & Anne-Marie C. Dingemans
To cite this article: Lizza E. L. Hendriks, Esther G. C. Troost, Allan Steward, Gerben P.
Bootsma, Katrien De Jaeger, Ben E. E. M. van den Borne & Anne-Marie C. Dingemans
(2014) Patient selection for whole brain radiotherapy (WBRT) in a large lung cancer cohort:
Impact of a new Dutch guideline on brain metastases, Acta Oncologica, 53:7, 945-951, DOI:
10.3109/0284186X.2014.906746
To link to this article:  https://doi.org/10.3109/0284186X.2014.906746
Published online: 23 Apr 2014. Submit your article to this journal 
Article views: 931 View related articles 
View Crossmark data Citing articles: 4 View citing articles 
 Correspondence: L. E. L. Hendriks, Department of Pulmonary Diseases, Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The 
Netherlands. Tel:    31 433871318. Fax:    31 433875051. E-mail: lizza.hendriks@mumc.nl 
 (Received  23  November  2013 ; accepted  15  March  2014 ) 
 ORIGINAL ARTICLE 
 Patient selection for whole brain radiotherapy (WBRT) in a large 
lung cancer cohort: Impact of a new Dutch guideline 
on brain metastases 
 LIZZA E. L.  HENDRIKS 1 ,  ESTHER G. C.  TROOST 2 ,  ALLAN  STEWARD 1 , 
 GERBEN P.  BOOTSMA 3 ,  KATRIEN  DE  JAEGER 4 ,  BEN E. E. M.  VAN DEN  BORNE 5  & 
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 1 Department of Pulmonary Diseases, GROW  – School for Oncology and Developmental Biology, Maastricht 
University Medical Center, Maastricht, The Netherlands,  2 Department of Radiation Oncology (Maastro Clinic), 
GROW  – School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The 
Netherlands,  3 Department of Pulmonary Diseases, Atrium Medical Center, Heerlen, The Netherlands,  4 Department of 
Radiotherapy, Catharina Hospital, Eindhoven, The Netherlands and  5 Department of Pulmonary Diseases, Catharina 
Hospital, Eindhoven, The Netherlands 
 ABSTRACT 
 Background. Median survival after diagnosis of brain metastases is, depending on the Recursive Partitioning Analysis 
(RPA) classes, 7.1 (class I) to 2.3 months (class III). In 2011 the Dutch guideline on brain metastases was revised, 
advising to withhold whole brain radiotherapy (WBRT) in RPA class III. In this large retrospective study, we evaluated 
the guideline ’ s use in daily practice. 
 Material and methods. Data of 428 lung cancer patients undergoing WBRT for brain metastases (2004 – 2012) 
referred from three Dutch hospitals were retrospectively analyzed. Details on Karnofsky performance score (KPS), age, 
control of primary tumor, extracranial metastases, histology, and survival after diagnosis of brain metastases were col-
lected. RPA class was determined using the fi rst four items. 
 Results. In total 327 patients had non-small cell lung cancer (NSCLC) and 101 small cell lung cancer (SCLC). 
For NSCLC, 6.1%, 71.9%, and 16.2% were classifi ed as RPA I, II, and III, respectively, and 5.8% could not be classi-
fi ed. For SCLC this was 8.9%, 66.3%, 14.9%, and 9.9%, respectively. Before the revised guideline was implemented, 
11.3 – 21.3% of WBRT patients were annually classifi ed as RPA III. In the year thereafter, this was 13.0% (p    0.646). 
Median survival (95% CI) for NSCLC RPA class I, II, and III was 11.4 (9.9 – 12.9), 4.0 (3.4 – 4.7), and 1.7 (1.3 – 2.0) 
months, respectively. For SCLC this was 7.9 (4.1 – 11.7), 4.7 (3.3 – 6.1), and 1.7 (1.5 – 1.8) months. 
 Conclusions. Although it is advised to withhold WBRT in RPA class III patients, in daily practice 11.3 – 21.3% of 
WBRT-treated patients were classifi ed as RPA III. The new guideline did not result in a decrease. Reasons for referral 
of RPA III patients despite a low KPS were not found. Despite WBRT, survival of RPA III patients remains poor and 
this poor outcome should be stressed in practice guidelines. Therefore, better awareness amongst physicians would 
prevent some patients from being treated unnecessarily. 
 More than 50% of all intracranial tumors are metas-
tases from extracranial primary tumor sites [1]. Of 
these primary tumors, lung cancer is the most fre-
quent [2] and 30 – 60% of lung cancer patients 
will develop brain metastases [3,4]. The Radiation 
Therapy Oncology Group (RTOG) has identifi ed 
pretreatment variables that determine survival after 
the diagnosis of brain metastases including age, 
Karnofsky performance status (KPS), control of pri-
mary tumor, absence of extracranial metastases 
and primary tumor site (e.g. breast cancer vs. lung 
cancer) [5]. Based on the Recursive Partitioning 
Acta Oncologica, 2014; 53: 945–951
ISSN 0284-186X print/ISSN 1651-226X online © 2014 Informa Healthcare
DOI: 10.3109/0284186X.2014.906746
946 L. E. L. Hendriks et al. 
Analysis (RPA) classifi cation using the above men-
tioned variables (except for primary tumor site) 
patients can be divided into three categories: class I 
with good prognosis, class II with intermediate and 
class III with poor prognosis (see Table I) [5]. RPA 
classifi cation has been validated in both non-small 
cell lung cancer (NSCLC) and small cell lung cancer 
(SCLC). Survival ranges from a median of 7.1 
months for RPA class I to 2.3 months for RPA class 
III [5 – 7]. Whole Brain Radiotherapy (WBRT) is con-
sidered the standard treatment for patients with brain 
metastases not eligible for (radio)surgery or stereot-
actic radiotherapy [8]. Potential benefi ts of WBRT 
are improved quality of life and performance status, 
improved neurological function, and a reduction in 
steroid dose needed to control neurological symp-
toms. However, the benefi t of WBRT as compared 
to best supportive care (BSC) alone has not been 
studied in randomized controlled trials [9]. 
 Moreover, data of an unplanned interim analysis 
(due to poor accrual) of the phase III QUARTZ trial 
(NCT00403065) comparing BSC with BSC plus 
WBRT in inoperable brain metastases from NSCLC 
indicate that, with BSC only, there is no evidence of 
worsening quality of life or overall survival in patients 
for whom clinician and patient are uncertain of the 
benefi t of WBRT [10]. 
 Current practice is that most guidelines (Euro-
pean Society of Medical Oncology, National Institute 
for Health and Clinical Excellence, National Com-
prehensive Cancer Network) advise WBRT combined 
with BSC without taking into account the RPA clas-
sifi cation or another prognostic classifi cation [11 –
 13]. However, in the revised Dutch guideline  ‘ brain 
metastases from solid tumors ’ (version 3.0, July 2011) 
it is advised to treat patients with more than three 
metastatic lesions in RPA class I and the majority 
of the patients in RPA class II actively with WBRT 
and to treat patients in RPA class III primarily 
symptomatically with BSC [14]. The performance 
score is often implemented in decision making in 
other guidelines but RPA classifi cation, although val-
idated, is not implemented in these guidelines. As 
RPA class seems strong in predicting early death [15], 
its use was advised in the revised Dutch guideline. 
 The aim of this study was to analyze whether the 
revised Dutch national guideline had impact on the 
selection of patients for WBRT, i.e. whether the per-
centage of RPA III patients who underwent WBRT 
decreased. Results for referral of RPA III patients 
despite a low performance score were also studied. 
Furthermore, the survival data of the studied patient 
cohort were compared to the survival reported in the 
RTOG validation studies [5]. 
 Material and methods 
 Patient selection 
 Data of 428 lung cancer patients from three teaching 
hospitals in the South of the Netherlands who under-
went WBRT for brain metastases between March 
2004 and July 2012 were retrospectively analyzed. 
WBRT was delivered at MAASTRO Clinic (Maas-
tricht) and the Catharina Hospital (Eindhoven). 
Details on age, gender, performance score (according 
to WHO/KPS), histology, local (intrathoracic) disease 
control, presence of extracranial metastases, time 
from diagnosis of lung cancer to development of 
brain metastases, and date of death or last follow-up 
visit were collected. Control of the primary tumor 
was defi ned as a complete tumor response or lack of 
local progression for at least three months before 
WBRT [based on chest x-ray or computed tomogra-
phy (CT) of the chest]. Diagnosis of extracranial 
metastases was based on CTs of the chest and upper-
abdomen, bone scintigraphy or ultrasound of the 
abdomen within one month of diagnosis of brain 
metastases. When only a chest x-ray was performed, 
the presence of extracranial metastases was stated as 
unknown. Brain metastases were defi ned as synchro-
nous if discovered at the time of diagnosis of the pri-
mary cancer or within two months thereafter [2]. The 
RPA class was determined using the following four 
items: KPS, age, local disease control and presence 
of extracranial metastases. Histology was divided into 
NSCLC and SCLC, whereby NSCLC was further 
subgrouped in squamous cell carcinoma, adenocarci-
noma, large cell carcinoma and  “ not otherwise spec-
ifi ed ” (NOS). Survival time was assessed from the 
date of diagnosis of brain metastases on imaging till 
death. Last date of follow-up was February 2013. The 
study was approved by the local science committee 
and was conducted according to the Code of Con-
duct for the use of data in Health Research and the 
Dutch  “ use of patient data ” law. 











I KPS    70 AND 






II all other patients 4.0 4.7 4.2
III KPS    70 1.7 1.7 2.3
 KPS, Karnofsky Performance Score; RPA, Recursive Partitioning 
Analysis. 
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 Statistical methods 
 All analyses were performed using SPSS statistical 
software (SPSS for Windows, version 20.0, IBM). 
Overall survival from time of diagnosis of brain 
metastases until death was calculated for all included 
NSCLC and SCLC patients per RPA class using the 
Kaplan-Meier method. A log rank test was performed 
to compare survival times between RPA classes. 
Pearson ’ s  χ 2 -test was used to evaluate whether there 
was a difference in RPA class III before and after 
implementation of the revised guideline. 
 Results 
 Patient characteristics 
 Between 2004 and 2012, a total of 327 NSCLC and 
101 SCLC patients underwent WBRT at two radio-
therapy departments. All patients received WBRT 
delivered with a 6 MV linear accelerator using two 
lateral fi elds. The prescribed dose was 5    4 Gy. In 
the NSCLC patient group, the mean age (range) was 
62.2 years (40.4 – 85.2), 55.4% was male and 266 
patients (81.3%) had a KPS of at least 70. In 208 
patients (63.6%) the primary tumor was uncon-
trolled, 139 (42.5%) had extracranial metastases and 
157 (48.0%) had brain metastases at primary diag-
nosis (Table II). 
 In the SCLC patient group, the mean age was 
64.0 years (44.7 – 85.7), 58.2% was male and 81 
(80.2%) had a KPS of at least 70. In 60 patients 
(59.4%) the primary tumor was not controlled, 43 
patients (42.6%) had extracranial metastases and 41 
patients (40.6%) had brain metastases at primary 
diagnosis (Table II). 
 RPA classifi cation 
 For NSCLC, 20 of 327 patients (6.1%) were classi-
fi ed as RPA I, 235 patients (71.9%) as RPA II, and 
53 (16.2%) as RPA III. RPA could not be defi ned in 
19 patients (5.8%). 
 For SCLC the corresponding numbers were 9 
(8.9%), 67 (66.3%), 15 (14.9%), and 10 (9.9%), 
respectively. 
 Survival 
 The majority of patients were dead at the time of 
analysis. Nine NSCLC patients (2.8%) and two 
SCLC patients (2.0%) were alive. For one NSCLC 
patient the date of death was unknown. These patients 
were classifi ed as censored observations at the time 
of last follow-up. Eight NSCLC (fi ve RPA II, three 
RPA III) and two SCLC (one RPA II, one RPA III) 
patients did not start or complete radiotherapy due 
to progressively deteriorating KPS. Since these 
patients were fi rst considered eligible for WBRT, they 
were included in the analysis with the intention to 
treat principle. 
 Table II. Patient characteristics. 
Patient characteristics
NSCLC 
N    327
SCLC 
N    101
Mean age (range) 62.2 (40.4 – 85.2) 62.1 (44.7 – 83.5)
% male 55.4 64.0
Histology
Adenocarcinoma 145 (44.3%)
Squamous cell carcinoma 37 (11.3%)
Large cell carcinoma 60 (18.3%)
Not otherwise specifi ed 85 (26.1%)
Performance (KPS)
   70 266 (81.3%) 81 (80.1%)
   70 53 (16.2%) 15 (14.9%)
Missing 8 (2.5%) 5 (5.0%)
Diagnosis of primary to development of BM
Synchronous 157 (48.0%) 41 (40.6%)
Metachronous 170 (52.0%) 60 (59.4%)
KPS    70, control of primary
Under control 41 (15.4%) 17 (21.0%)
Uncontrolled 208 (78.2%) 60 (74.1%)
Unknown 17 (6.4%) 4 (4.9%)
KPS    70, extracranial Metastases
No 104 (39.1%) 32 (39.5%)
Yes 146 (54.8%) 44 (54.3%)
Unknown 16 (6.1%) 5 (6.2%)
 BM, brain metastases; KPS, Karnofsky Performance Score; NSCLC, non-small cell lung cancer; SCLC, 
small cell lung cancer. 
948 L. E. L. Hendriks et al. 
 Median survival (95% CI) for NSCLC RPA class 
I, II, and III was 11.4 (9.9 – 12.9), 4.0 (3.4 – 4.7), and 
1.7 (1.3 – 2.0) months, respectively. This difference was 
statistically signifi cant (p    0.0001) (Figure 1A). For 
the NSCLC patients with an unknown RPA classifi ca-
tion, median survival was 2.7 (2.4 – 3.0) months. 
 For SCLC median survival (95% CI) for RPA 
class I, II, and III was statistically signifi cant different 
at 7.9 (4.1 – 11.7), 4.7 (3.3 – 6.1), and 1.7 (1.5 – 1.8) 
months, respectively (p    0.0001) (Figure 1B). For 
the SCLC patients with an unknown RPA class 
median survival was 4.2 (3.5 – 5.0) months. 
 In the large group of RPA class II patients a sub-
group analysis was performed to evaluate whether 
there were patient groups with different survival. 
Patients with extracranial metastases had a signifi -
cantly worse median survival compared to patients 
without [3.7 (2.8 – 4.5) vs. 5.7 (4.7 – 6.7) months 
(p    0.004)] Figure 1C. Age under or over 65 years 
had no impact, median survival was respectively 4.6 
(3.9 – 5.2) and 3.5 (2.8 – 4.1) months (p    0.472). The 
same was found for control or no control of primary 
tumor, median survival was respectively 3.5 (1.6 –
 5.4) and 4.3 (3.6 – 4.9) months (p    0.912). 
 RPA class III patients 
 In order to evaluate why RPA class III patients were 
treated despite a low KPS, a more detailed analysis 
was performed. 
 RPA class III patients were divided according to 
the presence or absence of extracranial metastases and 
to the presence of synchronous or metachronous brain 
metastases. Regarding the fi rst, it was hypothesized 
 Figure 1. (A) Survival post brain metastases in NSCLC patients per RPA class. (B) Survival post brain metastases in SCLC patients per 
RPA class. (C) Survival in RPA class II subgroups with and without extracranial metastases. 
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that RPA class III patients with solely brain metastases 
and no extracranial metastases at diagnosis were 
treated with WBRT despite a low KPS. 
 Regarding the latter, it was postulated that having 
a fi rst line systemic treatment option available could 
also be a reason to treat these patients (although pal-
liative systemic treatment is not recommended in 
patients with a low KPS, with a possible exception 
of SCLC patients because of high response rates to 
fi rst line chemotherapy). 
 However, the majority (60.0% of NSCLC and 
67.3% of SCLC) of RPA III patients was diagnosed 
with extracranial metastases, and 50.0% of NSCLC 
and 66.6% of SCLC patients had metachronous 
brain metastases. With the exception of SCLC 
patients diagnosed with synchronous brain metasta-
ses [only three patients, median survival 5.0 (0.0 –
 10.3) months], median survival for NSCLC and 
SCLC was 1.2 – 2.8 months (Table III). 
 Due to the low number of patients, groups were 
not further subdivided into controlled versus uncon-
trolled primary tumor. 
 Effect of the revised guideline 
 Before the revised Dutch national guideline was 
implemented in 2011, 11.3 – 21.3% of WBRT patients 
was annually classifi ed as RPA III (on average nine 
patients per year). In the year after implementing the 
guideline, this number only slightly dropped to 
13.0% (six patients per year) (p    0.646). 
 Discussion 
 Brain metastasis frequently occurs in lung cancer 
patients and is related with a poor outcome [3,4]. 
 Despite the recommendations in the Dutch 
national guideline, in our cohort 16.2% of NSCLC 
and 14.9% of SCLC patients treated with WBRT 
were RPA class III. Despite the release/implementa-
tion of the new national guideline in 2011, no sub-
stantial decrease in class III patients as percentage 
of the total of patients treated with WBRT was 
observed. 
 It is still largely unknown whether a poor overall 
prognosis is not only a poor prognostic factor for 
survival, but also a predictive factor for the poor 
effects of WBRT. In older studies (in which all 
patients were treated with WBRT) a poor perfor-
mance score was found to be a poor prognostic 
factor. In two recent studies (one interim-analysis 
only), this appeared to be also a poor predictive fac-
tor as there was no difference in survival between 
patients treated with and without WBRT [10,16]. 
 Our study confi rms the dismal outcome of these 
RPA III patients. A possible explanation for (con-
tinuing) treating RPA class III patients is that physi-
cians overestimate the benefi t of WBRT [17]. 
Furthermore, cancer patients and their relatives may 
have unrealistic expectations and are more often than 
non-cancer patients willing to accept an aggressive 
potentially toxic treatment with little or no benefi t 
on survival or quality of life [18]. 
 In our study no explanation was found for treat-
ing RPA class III patients despite their poor perfor-
mance score. Most of these patients were already 
treated with fi rst line chemotherapy and were not 
diagnosed with brain metastases as the only site of 
disease activity (i.e. they did not have a more favor-
able prognosis). 
 Potential benefi ts of WBRT are not well studied 
and there are no completed randomized trials of 
 Table III. RPA class III characteristics and survival. 











NSCLC (N    52)
With ECM
N (%) 35 (67.3) 14 (40.0) 1.7 (1.5 – 1.9) 21 (60.0) 1.5 (1.2 – 1.8)
Without ECM
N (%) 11 (21.2) 6 (54.5) 2.0 (0.1 – 3.8) 5 (45.5) 2.8 (0.0 – 7.7)
Unknown ECM
N (%) 6 (11.5) 3 (50.0) 1.7 (1.0 – 2.6) 3 (50.0) 1.5 (0.9 – 2.1)
SCLC (N    15)
With ECM
N (%) 9 (60.0) 3 (33.3) 5.0 (0.0 – 10.3) 6 (66.6) 1.7 (0.1 – 3.3)
Without ECM
N (%) 3 (20.0) 1 (33.3) 1.4 (N/A) 2 (66.6) 1.6 (N/A)
Unknown ECM
N (%) 3 (20.0) 0 (0.0) N/A 3 (100) 1.2 (0.5 – 2.0)
 BM, brain metastases; ECM, extracranial metastases; NSCLC, non-small cell lung cancer; RPA, 
Recursive Partitioning Analysis; SCLC, small cell lung cancer. 
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slightly different distribution of patients in the RPA 
classes compared to the original RTOG analysis [5]. 
In our study, less patients were classifi ed as RPA class 
I and more as RPA class II. In the only study validat-
ing RPA classifi cation for SCLC-only patients with 
brain metastases, more patients were classifi ed as RPA 
III (33% compared to 14.9% in our series) [7]. 
 Except for NSCLC RPA class I, survival data were 
comparable to the original RTOG analysis (Table I) 
[5] as well as to three lung cancer only studies [6,7,24]. 
It is possible that due to the small sample size our 
NSCLC RPA class I cohort is a highly selected group 
with a favorable histology and thus longer survival. 
Third, we did not have full data regarding patients 
who were evaluated by the radiation oncologist but 
were considered ineligible for WBRT. For those eval-
uated, low performance score was the main reason for 
ineligibility. Data regarding patients who were never 
considered candidates for WBRT by the treating pul-
monologist or multidisciplinary team were not retriev-
able. It would be interesting to investigate why some 
RPA class III patients are considered candidates for 
WBRT and some are not. 
 Fourth, only two radiotherapy departments (eas-
ily accessed by the three referral hospitals) were 
included in our analysis. This may not be representa-
tive for the whole country, however, the lack of use 
of RPA class in other guidelines suggests that the use 
of RPA III class is not common sense in selection of 
patients for WBRT. 
 Fifth, we did not have data regarding neurological 
outcome or quality of life after WBRT. However, 
other studies found no additive value of WBRT in 
RPA class III patients/patients with adverse prognos-
tic factors [10,16,23]. Considering the results in our 
study and bearing in mind the poor outcome of RPA 
class III patients, the use of RPA class for selection 
of lung cancer patients for WBRT should be stressed. 
At the moment the latter is most precisely described 
in the Dutch guideline, but in our opinion other 
guidelines should also stress the importance of select-
ing the right patients. To facilitate this, a prognostic 
classifi cation and not only performance status should 
be implemented in other guidelines. Physicians 
should be aware of their overestimation of the effect 
of WBRT on quality of life for the patient or even 
survival. Discussing disease prognosis, the effects 
and the side effects of WBRT with patients having 
brain metastases by their referring physicians is 
important. These patients should also be discussed 
in multidisciplinary meetings. 
 Conclusion 
 Although the Dutch guideline does not advise WBRT 
in RPA class III patients, 14.9 – 16.2% of the studied 
WBRT versus BSC with adequately defi ned end-
points. In older WBRT studies [19] symptomatic 
responses following WBRT of more than 60% were 
noted, but quality of life was not the primary end-
point. Also, response was not well defi ned, without 
any separation between response to corticosteroids 
or WBRT, and with measurement techniques that 
were neither standardized nor validated. More recent 
studies and a Cochrane review suggest that there is 
either only a modest effect of WBRT on quality of 
life and/or survival, or that no conclusion can be 
drawn [20 – 23]. Moreover, there is evidence that in 
NSCLC patients for whom the clinician (i.e. multi-
disciplinary lung/neuro-oncology team) and/or 
patient are uncertain of the benefi t of WBRT, with-
holding WBRT does not harm the patient. An 
unplanned interim analysis of the QUARTZ trial 
(N    151) indicated that there is no early evidence 
of worsening quality-adjusted life years (primary 
endpoint) for these NSCLC patients when treated 
with BSC only [10]. The total accrual of 534 patients 
in this study with a highly relevant primary endpoint 
for these patients is expected mid-2014. A recent 
retrospective study (N    113) in patients with brain 
metastases and adverse prognostic factors reported 
comparable results [16]. Another recent prospective 
non-randomized study (N    91) found no additive 
value of WBRT to optimal supportive care in RPA 
class III patients (predominantly NSCLC) [23]. 
 However, current practice is that most guidelines 
advise WBRT in addition to optimal supportive care 
[11 – 13]. Although the performance score is used for 
decision making in other guidelines, RPA classifi ca-
tion is not mentioned. Furthermore, according to 
our study, presence or absence of extracranial metas-
tases could be used in RPA class II to further refi ne 
the prognostic classifi cation in this group. In the 
original RTOG analysis, this retained no signifi cance, 
but it is possible that for lung cancer patients the 
presence of extracranial metastases is also a poor 
prognostic factor. 
 There are some drawbacks to this study. First of 
all, due to the retrospective design we were unable to 
collect all data (e.g. on performance status, control of 
primary tumor or extracranial metastases). In clinical 
routine, the evaluation of the extent of the intratho-
racic disease is somewhat arbitrary and the effort to 
evaluate the extent of extrathoracic disease is typically 
modest once the diagnosis of brain metastases is 
established. Despite this, evaluation of extracranial 
disease is important because of the prognostic impli-
cations as we have shown in the subgroup of RPA 
class II patients. Due to these missing data we were 
unable to determine the RPA class for all patients 
(5.8% of NSCLC patients and 9.9% of SCLC 
patients). Second, the retrospective nature led to a 
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WBRT patients were class RPA III. Despite the 
release/implementation of the new multidisciplinary 
national guideline in 2011, no decrease in referral of 
RPA class III patients for WBRT was observed. Rea-
sons for referral despite a low performance score 
were not found. The survival of RPA class III patients 
is poor and in agreement with the RTOG validation 
studies. In our view, guidelines should be imple-
mented more precisely and a prognostic classifi ca-
tion should also be implemented in other guidelines. 
Better awareness amongst physicians and correct 
information of patients on treatment expectations 
would prevent some patients from being treated 
unnecessarily. 
 Declaration of interest:  The authors report no 
confl icts of interest. The authors alone are respon-
sible for the content and writing of the paper. 
 References 
 Gavrilovic  IT ,  Posner  JB .  Brain metastases: Epidemiology [1] 
and pathophysiology .  J Neurooncol  2005 ; 75 : 5 – 14 . 
 Lagerwaard  FJ ,  Levendag  PC ,  Nowak  PJ ,  Eijkenboom  WM , [2] 
 Hanssens  PE ,  Schmitz  PI .  Identifi cation of prognostic factors 
in patients with brain metastases: A review of 1292 patients . 
 Int J Radiat Oncol Biol Phys  1999 ; 43 : 795 – 803 . 
 Ceresoli  GL ,  Reni  M ,  Chiesa  G ,  Carretta  A ,  Schipani  S , [3] 
 Passoni  P ,  et  al .  Brain metastases in locally advanced nons-
mall cell lung carcinoma after multimodality treatment: Risk 
factors analysis .  Cancer  2002 ; 95 : 605 – 12 . 
 Quan  AL ,  Videtic  GM ,  Suh  JH .  Brain metastases in small [4] 
cell lung cancer .  Oncology (Williston Park)  2004 ; 18 : 961 – 72 ; 
discussion 74, 79 – 80, 87. 
 Gaspar  L ,  Scott  C ,  Rotman  M ,  Asbell  S ,  Phillips  T , [5] 
 Wasserman  T ,  et  al .  Recursive partitioning analysis (RPA) of 
prognostic factors in three Radiation Therapy Oncology 
Group (RTOG) brain metastases trials .  Int J Radiat Oncol 
Biol Phys  1997 ; 37 : 745 – 51 . 
 Kepka  L ,  Cieslak  E ,  Bujko  K ,  Fijuth  J ,  Wierzchowski  M . [6] 
 Results of the whole-brain radiotherapy for patients with 
brain metastases from lung cancer: The RTOG RPA intra-
classes analysis .  Acta Oncol  2005 ; 44 : 389 – 98 . 
 Videtic  GM ,  Adelstein  DJ ,  Mekhail  TM ,  Rice  TW , [7] 
 Stevens  GH ,  Lee  SY ,  et  al .  Validation of the RTOG recursive 
partitioning analysis (RPA) classifi cation for small-cell lung 
cancer-only brain metastases .  Int J Radiat Oncol Biol Phys 
 2007 ; 67 : 240 – 3 . 
 Chu  FC ,  Hilaris  BB .  Value of radiation theray in the manage-[8] 
ment of intracranial metastases .  Cancer  1961 ; 14 : 577 – 81 . 
 Tsao  MN ,  Lloyd  N ,  Wong  R ,  Chow  E ,  Rakovitch  E , [9] 
 Laperriere  N .  Whole brain radiotherapy for the treatment of 
multiple brain metastases .  Cochrane Database Syst Rev 
 2006 ;( 3) :C D003869 . 
 Langley  RE ,  Stephens  RJ ,  Nankivell  M ,  Pugh  C ,  Moore  B , [10] 
 Navani  N ,  et  al .  Interim data from the Medical Research 
Council QUARTZ Trial: Does whole brain radiotherapy 
affect the survival and quality of life of patients with brain 
metastases from non-small cell lung cancer?  Clin Oncol 
 2013 ; 25 : e23 – 30 . 
 NICE clinical guideline 121: The diagnosis and treatment of [11] 
lung cancer .  2011 : 103 – 4 . 
 NCCN guidelines: Central nervous system cancers . version [12] 
2.2012.  2012 : MS – 25. 
 Peters  S ,  Adjei  AA ,  Gridelli  C ,  Reck  M ,  Kerr  K ,  Felip  E , [13] 
 et  al .  Metastatic non-small-cell lung cancer (NSCLC): 
ESMO Clinical Practice Guidelines for diagnosis, treatment 
and follow-up .  Ann Oncol  2012 ; 23(Suppl 7) : vii56 – 64 . 
 LWNO/ IKL richtlijn:  “ hersenmetastasen van solide tumoren ” . [14] 
2011:17 – 22. 
 Zindler  JD ,  Rodrigues  G ,  Haasbeek  CJ ,  De Haan  PF , [15] 
 Meijer  OW ,  Slotman  BJ ,  et  al .  The clinical utility of prognos-
tic scoring systems in patients with brain metastases treated 
with radiosurgery .  Radiother Oncol  2013 ; 106 : 370 – 4 . 
 Nieder  C ,  Norum  J ,  Dalhaug  A ,  Aandahl  G ,  Pawinski  A . [16] 
 Radiotherapy versus best supportive care in patients with 
brain metastases and adverse prognostic factors .  Clin Exp 
Metastasis  2013 ; 30 : 723 – 9 . 
 Barnes  EA ,  Chow  E ,  Tsao  MN ,  Bradley  NM ,  Doyle  M , [17] 
 Li  K ,  et  al .  Physician expectations of treatment outcomes for 
patients with brain metastases referred for whole brain radi-
otherapy .  Int J Radiat Oncol Biol Phys  2010 ; 76 : 187 – 92 . 
 Extermann  M ,  Albrand  G ,  Chen  H ,  Zanetta  S , [18] 
 Schonwetter  R ,  Zulian  GB ,  et  al .  Are older French patients 
as willing as older American patients to undertake chemo-
therapy?  J Clin Oncol  2003 ; 21 : 3214 – 9 . 
 Cairncross  JG ,  Kim  JH ,  Posner  JB .  Radiation therapy for [19] 
brain metastases .  Ann Neurol  1980 ; 7 : 529 – 41 . 
 Bezjak  A ,  Adam  J ,  Barton  R ,  Panzarella  T ,  Laperriere  N , [20] 
 Wong  CS ,  et  al .  Symptom response after palliative radio-
therapy for patients with brain metastases .  Eur J Cancer 
 2002 ; 38 : 487 – 96 . 
 Tsao  MN ,  Lloyd  N ,  Wong  RK ,  Chow  E ,  Rakovitch  E ,  Laper-[21] 
riere  N ,  et  al .  Whole brain radiotherapy for the treatment of 
newly diagnosed multiple brain metastases .  Cochrane Data-
base Syst Rev  2012 ; 4 :C D003869 . 
 Wong  J ,  Hird  A ,  Zhang  L ,  Tsao  M ,  Sinclair  E ,  Barnes  E ,  et  al . [22] 
 Symptoms and quality of life in cancer patients with brain 
metastases following palliative radiotherapy .  Int J Radiat 
Oncol Biol Phys  2009 ; 75 : 1125 – 31 . 
 Komosinska  K ,  Kepka  L ,  Niwinska  A ,  Pietrzak  L , [23] 
 Wierzchowski  M ,  Tyc-Szczepaniak  D ,  et  al .  Prospective eval-
uation of the palliative effect of whole-brain radiotherapy in 
patients with brain metastases and poor performance status . 
 Acta Oncol  2010 ; 49 : 382 – 8 . 
 Rodrigus  P ,  de Brouwer  P ,  Raaymakers  E .  Brain metastases [24] 
and non-small cell lung cancer. Prognostic factors and cor-
relation with survival after irradiation .  Lung Cancer  2001 ;
 32 : 129 – 36 . 
